Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16
JCI Insight · 08.07.2026 · 11 (13)
DOI: 10.1172/jci.insight.199983 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 08.07.2026. Verfasst von Matthew R Baldwin und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, …. Hauptthemen laut MEDLINE: COVID-19, Uteroglobin, Pulmonary Fibrosis, Lung. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND There are no known serum biomarkers that provide mechanistic insight or prognostic enrichment for post–COVID-19 pulmonary fibrosis. METHODS We tested associations of serum biomarkers with radiographic fibrosis-like abnormalities (reticulation, traction bronchiectasis, or honeycombing) on thoracic computed tomography (CT) scans 4 months, 15 months, and 3 years after hospitalization in an American discovery cohort of severe-to-critical COVID-19 survivors, and externally validated findings in 2 Canadian cohorts of moderate-to-critical COVID-19 survivors. In the discovery cohort, we investigated the dose-response relationship of the biomarker with CT-derived airway-to-lung ratio. We performed single-cell RNA sequencing (scRNA-seq) of transbronchial lung biopsies from COVID-19 survivors obtained 3 years after COVID-19 hospitalization and conducted immunofluorescence analysis of COVID-19 lung explants. RESULTS Among 150 discovery cohort participants, only higher levels of circulating club cell secretory protein-16 (CC16, encoded by the SCGB1A1 gene) at hospital discharge, 4 months, 15 months, and 3 years were associated with thoracic CT fibrosis-like abnormalities in cross-sectional and longitudinal analyses. Higher CC16 levels were associated with thoracic CT fibrosis-like abnormalities in 2 validation cohorts ( n = 56 and n = 37). CC16 levels were linearly associated with increased airway-to-lung ratio. scRNA-seq revealed increased proportions of epithelial cells expressing SCGB1A1 and SCGB1A1/MUC5B in COVID-19 survivors with fibrosis. Immunofluorescence analysis of COVID-19 lung explants demonstrated increased numbers of SCGB1A1-expressing epithelial cells only in small (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
- Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, New York, USA.
- Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York, USA.
- Department of Pathology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
- Department of Radiology, Internal Medicine, and Biomedical Engineering, University of Iowa, Iowa City, Iowa.
Förderung
- NHLBI NIH HHS
- NIH HHS
- NCATS NIH HHS
- US Department of Defense
- National Center for Advancing Translational Sciences
- Japan Society for the Promotion of Science
- National Heart, Lung, and Blood Institute
Zitieren
APA
Baldwin, M. R., Jones, A. E., Zhang, D., Gurung, C., Khan, Z., Saqi, A., Yang, X., Wei, Y., Nandakumar, R., Murphy, S. O., McGroder, C. F., Shaikh, F., Arcasoy, S., Benvenuto, L., Grewal, H., Smith, B. M., Hoffman, E. A., Yuen, A. C., Johal, P., …, & Garcia, C. K. (2026). Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16. JCI Insight, 11(13). https://doi.org/10.1172/jci.insight.199983
Vancouver
Baldwin MR, Jones AE, Zhang D, Gurung C, Khan Z, Saqi A, et al. Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16. JCI Insight. 2026;11(13). doi:10.1172/jci.insight.199983
BibTeX
@article{Baldwin2026,
author = {Baldwin, Matthew R and Jones, Ansley E and Zhang, David and Gurung, Chandan and Khan, Zain and Saqi, Anjali and Yang, Xuehan and Wei, Ying and Nandakumar, Renu and Murphy, Scarlett O and McGroder, Claire F and Shaikh, Faisal and Arcasoy, Selim and Benvenuto, Luke and Grewal, Harpreet and Smith, Benjamin M and Hoffman, Eric A and Yuen, Agnes Cy and Johal, Parteek and Carlsten, Christopher and Ryerson, Christopher J and Richards, J Brent and Wong, Alyson W and Nakanishi, Tomoko and Shah, Aditi S and Garcia, Christine Kim},
title = {Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {13},
doi = {10.1172/jci.insight.199983}
}
EUVIMED